Treatment of cancers with acquired resistance to kit inhibitors
US8680124B2 · kind B2 · utility
3Cited by
8References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 18, 2008 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | Jul 20, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.